"We will surely get to our destination if we join hands."
- Aung San Suu Kyi,  Burmese political leader 

DSEC is driven by an esteemed Advisory Board of industry executives who believe that idea sharing and discussion among safety leaders of different companies can make a positive impact in how the industry develops safer and more effective medicines for patients.  Each board member is an active participant in DSEC agenda planning as well as serving in an executive position at a prominent biopharmaceutical company.

Jack A. Reynolds, DVM, DACVP, DACLAM & FIATP
Chairman of the Advisory Board 
Drug Safety Executive Council

Werner Coussement
Global Head, PreClinical Development
Johnson & Johnson Pharma Group

Jim Green
Senior Vice President, Preclinical and Clinical Development Sciences
Biogen Idec

Eckhard von Keutz
Senior Vice President, Global Head of Toxicology
Bayer HealthCare AG

Klaus Krauser
Vice President, Global Head of Toxicology
Merck Serono

Ruth Lightfoot
Vice President, Comparative Biology & Safety Sciences
Amgen

Gregg Lundeen
Vice President, Toxicology
Eli Lilly

Peter Moldeus
Global Vice President, Drug Safety Evaluation
AstraZeneca

Thomas Singer
Global Head, Non Clinical Safety
F. Hoffmann-La Roche

Paul Trennery
Senior Vice President, Safety Assessments
GlaxoSmithKline